Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.